Analysis of individual ISGs composing the IFN score revealed that whereas many ISGs elevated in DS display reduced expression upon tofacitinib treatment (e.g. RSAD2, IFI44L), others do not (e.g. BPGM) (Figure 6b, Figure 6—figure supplement 1b). This evidence concerns the gene IFI44L and Dravet syndrome.